PDF(Pubmed)
Abstract：
As we move into the era of precision medicine, the growing relevance of genetic alterations to prostate cancer (PCa) development and treatment demonstrates the importance of characterizing preclinical models at the genomic level. Our study investigated the genomic characterization of eight PCa cell lines to understand which models are clinically relevant. We designed a custom AmpliSeq DNA gene panel that encompassed key molecular pathways targeting AR signaling, apoptosis, DNA damage repair, and PI3K/AKT/PTEN, in addition to tumor suppressor genes. We examined the relationship between cell line genomic alterations and therapeutic response. In addition, using DepMap\'s Celligner tool, we identified which preclinical models are most representative of specific prostate cancer patient populations on cBioPortal. These data will help investigators understand the genetic differences in preclinical models of PCa and determine which ones are relevant for use in their translational research.
摘要：
当我们进入精准医学时代,遗传改变与前列腺癌(PCa)发展和治疗的相关性日益增加,这表明在基因组水平上表征临床前模型的重要性.我们的研究调查了8种PCa细胞系的基因组特征，以了解哪些模型是临床相关的。我们设计了一个定制的AmpliSeqDNA基因组，涵盖了靶向AR信号传导的关键分子途径，凋亡，DNA损伤修复,和PI3K/AKT/PTEN，除了肿瘤抑制基因。我们检查了细胞系基因组改变与治疗反应之间的关系。此外,使用DepMap的Celligner工具，我们确定了哪些临床前模型在cBioPortal上最能代表特定前列腺癌患者人群.这些数据将帮助研究人员了解PCa临床前模型的遗传差异，并确定哪些与转化研究相关。
